Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

View:
Post by tcdrugs on Mar 09, 2010 12:04pm

paladin

You have to think Paladin is watching this very closely.  Goodman was asked at the last AGM if they planned on increasing their stake in ISA.  He said, "not at this time, but that doesn't mean we won't consider it in the future"
Comment by WASKERWISK on Mar 09, 2010 3:16pm
TC, I expect Goodman is watching very closely and Macbeth may be right that Palladin will look at a take over before the price gets out of reach. .The thing is though that Palladin has a pretty sweet deal already and may be a little reluctant to chance a break in the run of 14 successive record breaking years.  Plus any smell of a takeover and we are easily over a ...more  
Comment by labumba on Mar 09, 2010 4:00pm
Paladin will definitely their stake even just for investment purpose
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities